CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and ...

Korro Bio, Inc. ( (KRRO) ) has released its Q3 earnings. Here is a breakdown of the information Korro Bio, Inc. presented to its investors.

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Korro Bio (KRRO – Research Report). The associated price ...

Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA ...

Fintel reports that on October 21, 2024, Raymond James initiated coverage of Korro Bio (NasdaqCM:KRRO) with a Strong Buy ...

On Friday, H.C. Wainwright updated its outlook on Korro Bio Inc. (NASDAQ:KRRO) shares, increasing the price target to $115 from $100, while maintaining a Buy rating on the company's stock.

Korro Bio stock opened at $70.02 on Monday. Korro Bio has a fifty-two week low of $9.15 and a fifty-two week high of $98.00. The stock’s fifty day moving average is $43.72 and its two-hundred ...